Liedtke, M., Sun, Z., Litzow, M. R., Mattison, R. J., Paietta, E., Roberts, K. G., … Wieduwilt, M. J. (2024). Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial. In Blood (Vol. 144, pp. 779–779). American Society of Hematology. https://doi.org/10.1182/blood-2024-207557

Liedtke, Michaela, Zhuoxin Sun, Mark R. Litzow, Ryan J. Mattison, Elisabeth Paietta, Kathryn G. Roberts, Yanming Zhang, et al. “Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial.” In Blood, 144:779–779. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-207557.

Liedtke M, Sun Z, Litzow MR, Mattison RJ, Paietta E, Roberts KG, et al. Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial. In: Blood. American Society of Hematology; 2024. p. 779–779.

Liedtke, Michaela, et al. “Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 779–779. Crossref, doi:10.1182/blood-2024-207557.

Liedtke M, Sun Z, Litzow MR, Mattison RJ, Paietta E, Roberts KG, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Bergeron J, Wood BL, Zhao Y, Wu G, Chang T-C, Zhang W, Pratz KW, Dinner SN, Frey N, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Patel SB, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave R, Sharon E, Little R, Erba HP, Stone RM, Luger S, Mullighan CG, Tallman MS, Wieduwilt MJ. Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial. Blood. American Society of Hematology; 2024. p. 779–779.